Cardiff Oncology (NASDAQ:CRDF – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $0.09 million for the quarter.
Cardiff Oncology Trading Up 1.1 %
Shares of CRDF opened at $4.75 on Friday. The company’s 50 day simple moving average is $4.08 and its 200-day simple moving average is $3.16. The firm has a market cap of $242.89 million, a PE ratio of -5.05 and a beta of 1.77. Cardiff Oncology has a 12-month low of $1.65 and a 12-month high of $6.42.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on CRDF shares. HC Wainwright reduced their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday, November 8th. Piper Sandler upped their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday, December 13th.
Insider Buying and Selling at Cardiff Oncology
In other news, Director Gary W. Pace acquired 350,115 shares of Cardiff Oncology stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the completion of the transaction, the director now directly owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.80% of the stock is currently owned by corporate insiders.
About Cardiff Oncology
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
See Also
- Five stocks we like better than Cardiff Oncology
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- What Are the U.K. Market Holidays? How to Invest and Trade
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- What Does Downgrade Mean in Investing?
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
